217 related articles for article (PubMed ID: 20835521)
1. Methemoglobinemia and dapsone levels in patients with leprosy.
Vieira JL; Riveira JG; Martins Ade N; Silva JP; Salgado CG
Braz J Infect Dis; 2010; 14(3):319-21. PubMed ID: 20835521
[TBL] [Abstract][Full Text] [Related]
2. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
Penna GO; Bührer-Sékula S; Kerr LRS; Stefani MMA; Rodrigues LC; de Araújo MG; Ramos AMC; de Andrade ARC; Costa MB; Rosa PS; Gonçalves HS; Cruz R; Barreto ML; Pontes MAA; Penna MLF
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005725. PubMed ID: 28704363
[TBL] [Abstract][Full Text] [Related]
3. Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.
Gonçalves Hde S; Pontes MA; Bührer-Sékula S; Cruz R; Almeida PC; Moraes ME; Penna GO
Mem Inst Oswaldo Cruz; 2012 Dec; 107 Suppl 1():74-8. PubMed ID: 23283457
[TBL] [Abstract][Full Text] [Related]
4. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D
Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
6. Dapsone and body mass index in subjects with multibacillary leprosy.
Moura FM; Dias RM; Araujo EC; Brasil LM; Ferreira MV; Vieira JL
Ther Drug Monit; 2014 Apr; 36(2):261-3. PubMed ID: 24232126
[TBL] [Abstract][Full Text] [Related]
7. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
[TBL] [Abstract][Full Text] [Related]
8. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O
Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892
[TBL] [Abstract][Full Text] [Related]
9. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
10. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiologic mechanisms, diagnosis, and management of dapsone-induced methemoglobinemia.
Ashurst JV; Wasson MN; Hauger W; Fritz WT
J Am Osteopath Assoc; 2010 Jan; 110(1):16-20. PubMed ID: 20093649
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Borderline Lepromatous Leprosy Therapy Complicated by Type 1 Leprosy Reaction and Adverse Reactions with Dapsone and Clofazimine.
Matono T; Suzuki S; Mori S; Ato M
Am J Trop Med Hyg; 2024 Mar; 110(3):483-486. PubMed ID: 38266303
[TBL] [Abstract][Full Text] [Related]
14. Combined chemotherapy of multibacillary leprosy of 6 months' duration.
Onsun N; Saylan T; Pattyn SR
Lepr Rev; 1986; 57 Suppl 3():124-6. PubMed ID: 3573952
[No Abstract] [Full Text] [Related]
15. Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy.
Craig J; MacRae C; Melvin RG; Boggild AK
Am J Trop Med Hyg; 2019 May; 100(5):1145-1148. PubMed ID: 30915953
[TBL] [Abstract][Full Text] [Related]
16. Dapsone-induced methemoglobinemia in leprosy patients.
Kaur I; Mehta M; Agnihotri N; Dogra S; Ganguly NK
Int J Lepr Other Mycobact Dis; 2001 Sep; 69(3):247-9. PubMed ID: 11875770
[No Abstract] [Full Text] [Related]
17. Combined regimens of one year duration in the treatment of multibacillary leprosy--I. Combined regimens with rifampicin administered during one year.
Pattyn SR; Bourland J; Grillone S; Groenen G; Ghys P
Lepr Rev; 1989 Jun; 60(2):109-17. PubMed ID: 2671559
[TBL] [Abstract][Full Text] [Related]
18. The recognition, physiology, and treatment of medication-induced methemoglobinemia: a case report.
Turner MD; Karlis V; Glickman RS
Anesth Prog; 2007; 54(3):115-7. PubMed ID: 17900210
[TBL] [Abstract][Full Text] [Related]
19. Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.
Schalcher TR; Borges RS; Coleman MD; Batista Júnior J; Salgado CG; Vieira JL; Romão PR; Oliveira FR; Monteiro MC
PLoS One; 2014; 9(1):e85712. PubMed ID: 24465659
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and hematological side effects of clofazimine in leprosy patients.
Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
